Claims for Patent: 8,252,933
✉ Email this page to a colleague
Summary for Patent: 8,252,933
Title: | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
Abstract: | The present invention relates to new 2-oxo-1,2-dihydro-quinoline modulators of immune function, pharmaceutical compositions thereof, and methods of use thereof. ##STR00001## |
Inventor(s): | Gant; Thomas G. (Carlsbad, CA), Shahbaz; Manouchehr M. (Vista, CA) |
Assignee: | Teva Pharmaceuticals Industries, Ltd. (Petach-Tikva, IL) |
Application Number: | 12/552,663 |
Patent Claims: | 1. A compound of structural Formula I ##STR00029## or a salt thereof, wherein: R.sub.1-R.sub.17 are independently selected from the group consisting of hydrogen and
deuterium; and at least one of R1-R17 is deuterium.
2. The compound as recited in claim 1 wherein at least one of R.sub.1-R.sub.17 independently has deuterium enrichment of no less than about 10%. 3. The compound as recited in claim 1 wherein at least one of R.sub.1-R.sub.17 independently has deuterium enrichment of no less than about 50%. 4. The compound as recited in claim 1 wherein at least one of R.sub.1-R.sub.17 independently has deuterium enrichment of no less than about 90%. 5. The compound as recited in claim 1 wherein at least one of R.sub.1-R.sub.17 independently has deuterium enrichment of no less than about 98%. 6. The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of: ##STR00030## ##STR00031## ##STR00032## ##STR00033## 7. The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of ##STR00034## 8. The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 10%. 9. The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 50%. 10. The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 90%. 11. The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 98%. 12. The compound as recited in claim 7 wherein said compound has the structural formula: ##STR00035## 13. The compound as recited in claim 7 wherein said compound has the structural formula: ##STR00036## 14. The compound as recited in claim 7 wherein said compound has the structural formula: ##STR00037## 15. A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier. 16. A method of treatment of a immune function-mediated disorder comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof. 17. The method as recited in claim 16 wherein said disorder is multiple sclerosis and autoimmune disorders. 18. The method as recited in claim 16 further comprising the administration of an additional therapeutic agent. 19. The method as recited in claim 18 wherein said additional therapeutic agent is selected from the group consisting of immunomodulators and cyclosporins. 20. The method as recited in claim 19 wherein said immunomodulator is selected from the group consisting of filgrastim, molgramostim, sargramostim, lenograstim, ancestim, pegfilgrastim, interferon gamma, interferon alpha-2a, interferon alpha-2b, interferon alpha-n1, interferon beta-1a, interferon beta-1b, interferon alphacon-1, peginterferon alpha-2b, peginterferon alpha-2a, interferon omega, aldesleukin, oprelvekin, lentinan, roquinimex, BCG vaccine, pegademase, pidotimod, Poly I:C, Poly ICLC, thymopentin, immunocyanin, tasonermin, melanoma vaccine, glatiramer acetate, histamine dihydrochloride, mifamurtide, plerixefor, muromonab-CD3, antilymphocyte immunoglobulin (horse), antithymocyte immunoglobulin (rabbit), mycophenolic acid, sirolimus, leflunomide, alefacept, everolimus, gusperimus, efalizumab, abetimus, natalizumab, abatacept, eculizumab, etanercept, infliximab, afelimomab, adalimumab, certolizumab pegol, daclizumab, basiliximab, anakinra, ciclosporin, tacrolimus, azathioprine, thalidomide, methotrexate, and lenalidomide. 21. The method as recited in claim 16, further resulting in least one effect selected from the group consisting of: a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound; b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound. 22. The method as recited in claim 16, further resulting in at least two effects selected from the group consisting of: a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound; b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound. 23. The method as recited in claim 16, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound. 24. The method as recited in claim 23, wherein the cytochrome P450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6. 25. The method as recited claim 16, wherein said compound is characterized by decreased inhibition of at least one cytochrome P 450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound. 26. The method as recited in claim 25, wherein said cytochrome P450 or monoamine oxidase isoform is selected from the group consisting of CYPIAI, CYPIA2, CYPIBI, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2CI8, CYP2CI9, CYP2D6, CYP2EI, CYP2GI, CYP2J2, CYP2RI, CYP2SI, CYP3A4, CYP3A5, CYP3A5PI, CYP3A5P2, CYP3A7, CYP4AII, CYP4BI, CYP4F2, CYP4F3, CYP4F8, CYP4Fll, CYP4FI2, CYP4XI, CYP4ZI, CYP5AI, CYP7AI, CYP7BI, CYP8AI, CYP8BI, CYPIIAI, CYPIIBI, CYPIIB2, CYPI7, CYPI9, CYP21, CYP24, CYP26AI, CYP26BI, CYP27AI, CYP27BI, CYP39, CYP46, CYP51, MAOA, and MAOB. 27. The method as recited in claim 16, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound. 28. The method as recited in claim 27, wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase ("ALT"), serum glutamic-pyruvic transaminase ("SGPT"), aspartate aminotransferase ("AST," "SGOT"), ALT/AST ratios, serum aldolase, alkaline phosphatase ("ALP"), ammonia levels, bilirubin, gamma-glutamyl transpeptidase ("GGTP," ".gamma.-GTP," "GGT"), leucine aminopeptidase ("LAP"), liver biopsy, liver ultrasonography, liver nuclear scan, 5'-nucleotidase, and blood protein. |
Details for Patent 8,252,933
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Teknika Llc | N/A | bcg vaccine | For Injection | 103050 | 06/21/1989 | ⤷ Try a Trial | 2028-09-03 |
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2028-09-03 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2028-09-03 |
Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2028-09-03 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | For Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2028-09-03 |
Partner Therapeutics, Inc. | LEUKINE | sargramostim | Injection | 103362 | 03/05/1991 | ⤷ Try a Trial | 2028-09-03 |
Centocor Ortho Biotech Products, L.p. | ORTHOCLONE OKT3 | muromanab-cd3 | Injection | 103463 | 09/14/1992 | ⤷ Try a Trial | 2028-09-03 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.